2. Search Result
Search Result
Results for "

firing

" in MedChemExpress (MCE) Product Catalog:

25

Inhibitors & Agonists

1

Fluorescent Dye

1

Peptides

2

Natural
Products

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-78036
    Mesaconic acid

    Citronic acid; Methylfumaric acid

    		 Endogenous Metabolite Others
    Mesaconic acid is an active product that can be extracted from Saxifraga stolonifera. Mesaconic acid is used as a fire retardant and is a competitive inhibitor of fumarate reduction .
    Mesaconic acid
  • HY-103474
    Bicuculline methiodide
    20+ Cited Publications

    (-)-Bicuculline methiodide; l-Bicuculline methiodide

    		 GABA Receptor Neurological Disease
    Bicuculline methiodide is a potent GABA(A) receptors blocker. Bicuculline methiodide alters membrane properties and firing pattern. Bicuculline methiodide reduces the Apamin-sensitive afterhyperpolarization, while Apamin is a toxin isolated from bee venom to block small conductance Ca 2+ -activated K + channels. Bicuculline methiodide facilitates burst firing via blocking apamin-sensitive Ca 2+ -activated K + current .
    Bicuculline methiodide
  • HY-N4250
    Periplocoside N

    		Others Infection
    Periplocoside N, a pregnane glycoside isolated from root powder of Periploca sepium, possesses insecticidal activities against the red imported fire ant .
    Periplocoside N
  • HY-B1657A
    Fosphenytoin disodium

    		Sodium Channel Neurological Disease
    Fosphenytoin sodium is a phenytoin proagent with similar anticonvulsant properties. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repetitive firing of action potentials.
    Fosphenytoin disodium
  • HY-133528
    OptoBI-1

    		TRP Channel Neurological Disease
    OptoBI-1 is a photochromic TRPC3 agonist, which asts as a photopharmacological tool to control of neuronal firing .
    OptoBI-1
  • HY-10351A
    Robalzotan hydrochloride

    NAD-​299 hydrochloride

    		 5-HT Receptor Neurological Disease
    Robalzotan hydrochloride (NAD-​299 hydrochloride) is a potent and selective 5-Hydroxytryptamine 1A (5-HT1A) inhibitor. Robalzotan hydrochloride increases the firing rate of 5-HT cells. Robalzotan hydrochloride induces 5-HT1A receptor occupancy. Robalzotan hydrochloride has the potential for the research of a cholinergic deficit in the central -nervous system .
    Robalzotan hydrochloride
  • HY-10351
    Robalzotan

    NAD-​299

    		 5-HT Receptor Neurological Disease
    Robalzotan (NAD-​299) is a potent and selective 5-Hydroxytryptamine 1A (5-HT1A) inhibitor. Robalzotan increases the firing rate of 5-HT cells. Robalzotan induces 5-HT1A receptor occupancy. Robalzotan has the potential for the research of a cholinergic deficit in the central -nervous system .
    Robalzotan
  • HY-121248
    Hydramethylnon

    AC217300

    		 Mitochondrial Metabolism Infection
    Hydramethylnon (AC217300) is an amidinohydrazone insecticide. Hydramethylnon's mechanism of action is through inhibition of mitochondrial respiration by inhibiting the electron transport chain at the cytochrome b-c1 complex. Hydramethylnon can be used to eliminate red imported fire ants, cockroaches, and other insects .
    Hydramethylnon
  • HY-10955
    TTA-P1

    		Calcium Channel Neurological Disease
    TTA-P1 is a potent state-independent compound inhibiting human T-type calcium channel. T-type calcium channels play a role in diverse physiological responses including neuronal burst firing, hormone secretion, and cell growth. TTA-P1 has the potential for the research of absence epilepsy .
    TTA-P1
  • HY-125928
    AA43279

    		Sodium Channel Neurological Disease
    AA43279 is an in gamma-aminobutyric acid (GABA) fast-firing interneurons located activator for Nav1.1 channel (SCN1A) with an EC50 of 9.5 μM. AA43279 enhances specific neuronal firing activity in vitro, and exhibits anticonvulsant activity in rat MEST model .
    AA43279
  • HY-118461
    PD 120697

    		Dopamine Receptor Neurological Disease
    PD 120697 is an orally active dopamine (DA) agonist. PD 120697 inhibits striatal DA synthesis, DA neuronal firing, spontaneous locomotor activity, and reverses Reserpine (HY-N0480)-induced depression .
    PD 120697
  • HY-119990
    Fotocaine

    		Biochemical Assay Reagents Neurological Disease Inflammation/Immunology
    Fotocaine is a photochromic blocker of voltage-gated ion channels. Fotocaine is readily taken up by neurons in brain slices and enables optical control of action potential firing by switching between 350 and 450 nm light. Fotocaine can be used in analgesia research .
    Fotocaine
  • HY-B1657AS
    Fosphenytoin-d10 disodium

    		Isotope-Labeled Compounds Sodium Channel Neurological Disease
    Fosphenytoin-d10 (disodium) is deuterium labeled Fosphenytoin (disodium). Fosphenytoin sodium is a phenytoin proagent with similar anticonvulsant properties. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repetitive firing of action potentials.
    Fosphenytoin-d10 disodium
  • HY-D1517
    FM 2-10

    		Fluorescent Dye Others
    FM 2-10 is a fluorescent dye. FM 2-10 is a less hydrophobic version of FM 1-43 (HY-D1434). FM 2-10 can be used for identifying actively firing neurons and investigating the mechanisms of activity-dependent vesicle cycling .
    FM 2-10
  • HY-118706
    PD 118440

    		Dopamine Receptor Neurological Disease
    PD 118440 is an orally active dopamine (DA) agonist. PD 118440 has significant central nervous system effects, including inhibition of striatal DA synthesis, suppression of DA neuron firing, and reversal of Reserpine (HY-N0480)-induced depression in rats .
    PD 118440
  • HY-B1657AR
    Fosphenytoin (disodium) (Standard)

    		Sodium Channel Neurological Disease
    Fosphenytoin (disodium) (Standard) is the analytical standard of Fosphenytoin (disodium). This product is intended for research and analytical applications. Fosphenytoin sodium is a phenytoin proagent with similar anticonvulsant properties. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repetitive firing of action potentials.
    Fosphenytoin (disodium) (Standard)
  • HY-100539
    PD 128907

    		Dopamine Receptor Others
    PD 128907 is a D3 receptor ligand with activities of activating dopamine receptors, inhibiting cell firing, and inhibiting dopamine release. The active (+) enantiomer of PD 128907 has high affinity and selectivity for rat D3 dopamine receptors. PD 128907 inhibits cell firing in the ventral tegmental area and substantia nigra pars compacta with EC50 values of 33nM and 38nM, respectively. PD 128907 also inhibits dopamine release in the caudate putamen with an EC50 of 66nM. However, the selective D2 receptor antagonist L-741,626 has high affinity for receptors activated by PD 128907, indicating that the effects of PD 128907 are more likely on D2 autoreceptors rather than D3 dopamine receptor subtypes.
    PD 128907
  • HY-119775
    U92016A

    		Others Others
    U92016A is a potent and selective agonist of the 5-HT1A receptor, with activities such as high affinity binding to the 5-HT1A receptor in vitro, causing a decrease in body temperature in vivo, and high potency and high intrinsic activity as an agonist in single-cell firing studies.
    U92016A
  • HY-113316A
    (±)-Salsolinol hydrochloride

    		Endogenous Metabolite Opioid Receptor Neurological Disease
    (±)-Salsolinol hydrochloride is the hydrochloride form of (±)-Salsolinol (HY-113316). (±)-Salsolinol hydrochloride is a Dopamine (HY-B0451)-derived endogenous metabolite. (±)-Salsolinol hydrochloride activates μ-opioid receptors (MORs), reduces GABAergic transmission, increases the excitability of dopamine (DA) neurons, and thus accelerates the sustained firing of neurons in the posterior ventral tegmental area (pVTA) .
    (±)-Salsolinol hydrochloride
  • HY-148502
    VU6019650

    		mAChR Neurological Disease
    VU6019650 is a potent and selective orthosteric antagonist of M5 mAChR (IC50=36 nM), can be used for opioid use disorder (OUD) relief. VU6019650 can cross blood brain barrier, potentially modulates the mesolimbic dopaminergic reward circuitry. VU6019650 blocks Oxotremorine M iodide (HY-101372A) induced increases of neuronal firing rates of midbrain dopamine neurons in the ventral tegmental area (VTA) .
    VU6019650
  • HY-100481
    RP 72540

    RPR101048

    		 Cholecystokinin Receptor Neurological Disease
    RP 72540 is a selective CCK-B receptor antagonist, with IC50 values of 2.4, 1.2, and 3.8 nM for CCK-B receptors in the guinea pig cerebral cortex, rat cerebral cortex, and mouse brain, respectively. RP 72540 effectively inhibits CCK-8-induced neuronal firing and dose-dependently inhibits gastric acid secretion, making it potentially valuable in studies of acid secretion. RP 72540 is an important tool for investigating the physiological functions of CCK B receptors .
    RP 72540
  • HY-P3467
    (Thr4,Gly7)-Oxytocin

    		Oxytocin Receptor Potassium Channel Neurological Disease
    (Thr4,Gly7)-Oxytocin, an Oxytocin analogue, is a specific OT receptor agonist. (Thr4,Gly7)-Oxytocin also excites subicular neurons via activation of TRPV1 channels, and depression of K + channels. .
    (Thr4,Gly7)-Oxytocin
  • HY-147319
    RTI-7470-44

    		Others Neurological Disease
    RTI-7470-44 is a potent, selective and blood-brain barrier (BBB) penetrant human trace amine-associated receptor subtype 1 (hTAAR1) antagonist with an IC50 value of 8.4 nM and a Ki value of 0.3 nM. RTI-7470-44 has moderate metabolic stability, and a favorable preliminary off-target profile. RTI-7470-44 can increase the spontaneous firing rate of mouse ventral tegmental area (VTA) dopaminergic neurons. RTI-7470-44 can be used for researching schizophrenia, agent addiction, and Parkinson’s disease (PD) .
    RTI-7470-44
  • HY-157802
    LTGO-33

    		Sodium Channel Neurological Disease
    LTGO-33 is a potent and selective voltage-gated sodium channel NaV1.8 inhibitor. LTGO-33 inhibits NaV1.8 in the nM potency range and exhibits over 600-fold selectivity against human NaV1.1-NaV1.7 and NaV1.9. LTGO-33 exhibits state-independent inhibition with similar potencies on channels in the closed and inactivated conformations. LTGO-33 inhibits native TTX-R NaV1.8 currents in non-human primate and human DRG neurons, where it reduces action potential firing. LTGO-33 can be used for pain disorders research .
    LTGO-33
  • HY-W013712
    GI-530159

    		Potassium Channel Neurological Disease
    GI-530159 is a selective opener of TREK1 and TREK2 potassium channels. GI-530159 displays selectivity for TREK1/2 over TRAAK, TASK3 and other potassium channels, with an EC50 of 0.76 μM for TREK1. GI-530159 reduces rat dorsal root ganglion neuron excitability and shows potential analgesic effect .
    GI-530159

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: